These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Key targets of hormone treatment of prostate cancer. Part I: the androgen receptor and steroidogenic pathways. Pitts WR BJU Int; 2009 Nov; 104(9):1304. PubMed ID: 19824968 [No Abstract] [Full Text] [Related]
4. [The loss of androgen-dependency and its molecular mechanism]. Sato B; Nakamura N; Nonomura N; Matsumoto K Gan No Rinsho; 1989 May; Spec No():261-7. PubMed ID: 2689666 [No Abstract] [Full Text] [Related]
5. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. Vis AN; Schröder FH BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559 [TBL] [Abstract][Full Text] [Related]
6. Complete androgen blockade for the treatment of prostate cancer. Labrie F; Dupont A; Belanger A Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740 [No Abstract] [Full Text] [Related]
7. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Baretton GB; Klenk U; Diebold J; Schmeller N; Löhrs U Br J Cancer; 1999 May; 80(3-4):546-55. PubMed ID: 10408865 [TBL] [Abstract][Full Text] [Related]
8. [Mechanism of loss of androgen dependency in androgen-dependent tumor]. Sato N; Suzuki H; Shimazaki J Hum Cell; 1993 Sep; 6(3):170-5. PubMed ID: 8297812 [TBL] [Abstract][Full Text] [Related]
9. Intra-prostatic androgen levels during various androgen-blockade regimens. Nishiyama T Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782 [TBL] [Abstract][Full Text] [Related]
10. Hormonal therapy of prostate cancer: current concepts and future prospects. Smith JA Clin Ther; 1988; 10(3):281-6. PubMed ID: 3078908 [TBL] [Abstract][Full Text] [Related]
11. [Prostatic carcinoma. I: Androgen dependency of prostatic carcinoma]. Shimazaki J; Fuse H; Akimoto S; Sumiya H; Akakura K; Ichikawa T Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):909-16. PubMed ID: 3389834 [TBL] [Abstract][Full Text] [Related]
13. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Joseph IB; Isaacs JT Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270 [TBL] [Abstract][Full Text] [Related]
14. [Modern approaches to treating locally-advanced and disseminated prostate cancer]. Veliev EI Ter Arkh; 2002; 74(10):67-70. PubMed ID: 12469638 [No Abstract] [Full Text] [Related]
15. Evolution of the androgen receptor pathway during progression of prostate cancer. Hendriksen PJ; Dits NF; Kokame K; Veldhoven A; van Weerden WM; Bangma CH; Trapman J; Jenster G Cancer Res; 2006 May; 66(10):5012-20. PubMed ID: 16707422 [TBL] [Abstract][Full Text] [Related]
16. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359 [TBL] [Abstract][Full Text] [Related]
17. [Hormonal treatment in cancer of the prostate]. Boccon-Gibod L Rev Prat; 1987 Feb; 37(7):386-90. PubMed ID: 3823774 [No Abstract] [Full Text] [Related]